The tumor-to-heart ratio was found to be increased in mice receiving XRT and anti-CTLA-4 therapy (p = 0.0246), but no difference was found in the tumor-to-muscle, spleen-to-heart, or spleen-to-muscle ratios among treatment groups. This evidence concerns the gene CTLA4 and neoplasm.